Quotient Clinical Builds a U.S. CRO Presence

The clinical research (CRO) market in the United States has attracted the interest of foreign investors looking to build up their platforms overseas. Quotient Clinical, a privately-held CRO based in Edinburgh, Scotland, acquired two U.S.-based CROs in February 2017, in an effort to bring its innovative Translational Pharmaceutics ® platform to America. But this CRO had to change a few hands over the past few years before it could reach acquirer status. In December 2013, the U.K.-based Quotient Bioresearch Group sold Quotient Clinical to London-based Bridgepoint Development Capital, marking Bridgepoint’s entry into a growing CRO market. Just two years later, in December 2015,... Read More »